Core Insights - IFF is expanding its operations in Latin America by establishing a fermentation-based enzyme production hub in Argentina and a household care application laboratory in Brazil, aimed at enhancing its Health & Biosciences business in the region [1] Group 1: Expansion and Innovation - The Arroyito site in Argentina will be transformed into IFF's first full fermentation-based enzyme production hub in Latin America, allowing for local production of high-performance enzymes [1] - The new household care application laboratory in Brazil will enable customers to evaluate and optimize enzyme performance for laundry and dishwashing applications, facilitating faster testing and improved formulation accuracy [1] - IFF's investment in these facilities is expected to improve speed, reliability, and locally relevant solutions for various markets, including brewing, animal nutrition, biofuels, and home care [1] Group 2: Market Growth and Commitment - Latin America is identified as one of the fastest-growing markets for IFF, with a strong emphasis on bioscience-enabled solutions [1] - The company aims to build deeper partnerships with customers and teams across the region to foster sustained innovation and shared growth [1] - IFF's long-term commitment to the region is reinforced by over four decades of industrial biotechnology leadership, positioning the company to capture future growth across multiple sectors [1]

Core Viewpoint - IFF has declared a quarterly cash dividend of $0.40 per share and completed the divestiture of its soy crush, concentrates, and lecithin businesses to Bunge, while also reporting its financial results for the fourth quarter and full year of 2025. Dividend Declaration - IFF's Board of Directors declared a regular quarterly cash dividend of $0.40 per share, payable on April 10, 2026, to shareholders of record as of March 20, 2026 [1]. Divestiture Announcement - IFF successfully completed the divestiture of its soy crush, concentrates, and lecithin businesses to Bunge, excluding the soy isolates business [1]. Financial Results - For the full year 2025, IFF reported consolidated sales of $10.9 billion, a loss before taxes of $412 million, and an earnings per share (EPS) of $(1.46). The operating EBITDA was $2.1 billion with an operating EBITDA margin of 19.2%, and an EPS excluding amortization of $4.20 [1].